drugset / Trial / NCT04486781
A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to evaluate the combination of Pembrolizumab + sEphB4-HSA in the population of patients with previously untreated advanced (metastatic or recurrent) urothelial carcinoma who are chemotherapy ineligible or who refuse chemotherapy.
Timeline
- Start
- 2020-08-14
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | sEphB4-HSA | Protein / enzyme biologic | — | Intravenous |